Exact Sciences Corp (EXAS) Misses Q2 EPS by 1c
Exact Sciences Corp (NASDAQ: EXAS) reported Q2 EPS of ($0.19), $0.01 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.02 million.
"With the completion of Exact's submission to the FDA for Cologuard, our colorectal cancer screening test, the company's top priorities are commercial readiness and operational excellence," said Kevin T. Conroy, the company’s president and CEO. “The entire team at Exact is focused on building a strong foundation from which we can launch Cologuard, pending FDA approval. All of us understand the potential impact of Cologuard and we look forward to bringing it to patients."
For earnings history and earnings-related data on Exact Sciences Corp (EXAS) click here.
"With the completion of Exact's submission to the FDA for Cologuard, our colorectal cancer screening test, the company's top priorities are commercial readiness and operational excellence," said Kevin T. Conroy, the company’s president and CEO. “The entire team at Exact is focused on building a strong foundation from which we can launch Cologuard, pending FDA approval. All of us understand the potential impact of Cologuard and we look forward to bringing it to patients."
For earnings history and earnings-related data on Exact Sciences Corp (EXAS) click here.